-
1
-
-
84871622500
-
Therapeutic antibodies: Market considerations, disease targets and bioprocessing
-
J.G. Elvin, R.G. Couston, and C.F. van der Walle Therapeutic antibodies: market considerations, disease targets and bioprocessing Int J Pharm 440 2013 83 98
-
(2013)
Int J Pharm
, vol.440
, pp. 83-98
-
-
Elvin, J.G.1
Couston, R.G.2
Van Der Walle, C.F.3
-
2
-
-
84860896956
-
Marketed therapeutic antibodies compendium
-
J.M. Reichert Marketed therapeutic antibodies compendium MAbs 4 2012 413 415
-
(2012)
MAbs
, vol.4
, pp. 413-415
-
-
Reichert, J.M.1
-
3
-
-
0034663798
-
Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor
-
A.P. West Jr., and P.J. Bjorkman Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor Biochemistry 39 2000 9698 9708
-
(2000)
Biochemistry
, vol.39
, pp. 9698-9708
-
-
West, A.P.1
Bjorkman, P.J.2
-
4
-
-
0035012654
-
Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: Mechanism of pH-dependent binding
-
W.L. Martin, A.P. West Jr., L. Gan, and P.J. Bjorkman Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding Mol Cell 7 2001 867 877
-
(2001)
Mol Cell
, vol.7
, pp. 867-877
-
-
Martin, W.L.1
West, A.P.2
Gan, L.3
Bjorkman, P.J.4
-
5
-
-
84876556946
-
Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant
-
F. Mimoto, T. Igawa, T. Kuramochi, H. Katada, S. Kadono, T. Kamikawa, and et al. Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant MAbs 5 2013 229 236
-
(2013)
MAbs
, vol.5
, pp. 229-236
-
-
Mimoto, F.1
Igawa, T.2
Kuramochi, T.3
Katada, H.4
Kadono, S.5
Kamikawa, T.6
-
6
-
-
84878931351
-
Targeting T cells to tumor cells using bispecific antibodies
-
S.R. Frankel, and P.A. Baeuerle Targeting T cells to tumor cells using bispecific antibodies Curr Opin Chem Biol 17 2013 385 392
-
(2013)
Curr Opin Chem Biol
, vol.17
, pp. 385-392
-
-
Frankel, S.R.1
Baeuerle, P.A.2
-
7
-
-
84884272080
-
Potential therapeutic roles for antibody mixtures
-
T.S. Raju, and W.R. Strohl Potential therapeutic roles for antibody mixtures Expert Opin Biol Ther 13 2013 1347 1352
-
(2013)
Expert Opin Biol Ther
, vol.13
, pp. 1347-1352
-
-
Raju, T.S.1
Strohl, W.R.2
-
8
-
-
84907983318
-
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
-
S.Y. Ko, A. Pegu, R.S. Rudicell, Z.Y. Yang, M.G. Joyce, X. Chen, and et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection Nature 514 2014 642 645
-
(2014)
Nature
, vol.514
, pp. 642-645
-
-
Ko, S.Y.1
Pegu, A.2
Rudicell, R.S.3
Yang, Z.Y.4
Joyce, M.G.5
Chen, X.6
-
9
-
-
17644441947
-
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics
-
J. Corne, R. Djukanovic, L. Thomas, J. Warner, L. Botta, B. Grandordy, and et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics J Clin Invest 99 1997 879 887
-
(1997)
J Clin Invest
, vol.99
, pp. 879-887
-
-
Corne, J.1
Djukanovic, R.2
Thomas, L.3
Warner, J.4
Botta, L.5
Grandordy, B.6
-
10
-
-
84869798948
-
Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies
-
D.L. Mortensen, S. Prabhu, E.G. Stefanich, S. Kadkhodayan-Fischer, T.R. Gelzleichter, D. Baker, and et al. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies MAbs 4 2012 724 731
-
(2012)
MAbs
, vol.4
, pp. 724-731
-
-
Mortensen, D.L.1
Prabhu, S.2
Stefanich, E.G.3
Kadkhodayan-Fischer, S.4
Gelzleichter, T.R.5
Baker, D.6
-
11
-
-
84871156077
-
A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics
-
P. Hodsman, C. Ashman, A. Cahn, E. De Boever, N. Locantore, A. Serone, and et al. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics Br J Clin Pharmacol 75 2013 118 128
-
(2013)
Br J Clin Pharmacol
, vol.75
, pp. 118-128
-
-
Hodsman, P.1
Ashman, C.2
Cahn, A.3
De Boever, E.4
Locantore, N.5
Serone, A.6
-
12
-
-
78649656830
-
Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys
-
J.J. Xiao, W. Krzyzanski, Y.M. Wang, H. Li, M.J. Rose, M. Ma, and et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys AAPS J 12 2010 646 657
-
(2010)
AAPS J
, vol.12
, pp. 646-657
-
-
Xiao, J.J.1
Krzyzanski, W.2
Wang, Y.M.3
Li, H.4
Rose, M.J.5
Ma, M.6
-
13
-
-
20044381863
-
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer
-
G.C. Jayson, C. Mulatero, M. Ranson, J. Zweit, A. Jackson, L. Broughton, and et al. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer Eur J Cancer 41 2005 555 563
-
(2005)
Eur J Cancer
, vol.41
, pp. 555-563
-
-
Jayson, G.C.1
Mulatero, C.2
Ranson, M.3
Zweit, J.4
Jackson, A.5
Broughton, L.6
-
14
-
-
79958849218
-
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival
-
R.J. Kelly, A. Hill, L.M. Arnold, G.L. Brooksbank, S.J. Richards, M. Cullen, and et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival Blood 117 2011 6786 6792
-
(2011)
Blood
, vol.117
, pp. 6786-6792
-
-
Kelly, R.J.1
Hill, A.2
Arnold, L.M.3
Brooksbank, G.L.4
Richards, S.J.5
Cullen, M.6
-
16
-
-
78149320579
-
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
-
T. Igawa, S. Ishii, T. Tachibana, A. Maeda, Y. Higuchi, S. Shimaoka, and et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization Nat Biotechnol 28 2010 1203 1207
-
(2010)
Nat Biotechnol
, vol.28
, pp. 1203-1207
-
-
Igawa, T.1
Ishii, S.2
Tachibana, T.3
Maeda, A.4
Higuchi, Y.5
Shimaoka, S.6
-
17
-
-
84877147797
-
Engineered monoclonal antibody with novel antigen-sweeping activity in vivo
-
T. Igawa, A. Maeda, K. Haraya, T. Tachibana, Y. Iwayanagi, F. Mimoto, and et al. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo PLoS One 8 2013 e63236
-
(2013)
PLoS One
, vol.8
-
-
Igawa, T.1
Maeda, A.2
Haraya, K.3
Tachibana, T.4
Iwayanagi, Y.5
Mimoto, F.6
-
18
-
-
85027938012
-
PH-dependent antigen-binding antibodies as a novel therapeutic modality
-
T. Igawa, F. Mimoto, and K. Hattori pH-dependent antigen-binding antibodies as a novel therapeutic modality Biochim Biophys Acta 1844 2014 1943 1950
-
(2014)
Biochim Biophys Acta
, vol.1844
, pp. 1943-1950
-
-
Igawa, T.1
Mimoto, F.2
Hattori, K.3
-
19
-
-
33745053380
-
The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab
-
B. Wu, A. Joshi, S. Ren, and C. Ng The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab J Pharm Sci 95 2006 1258 1268
-
(2006)
J Pharm Sci
, vol.95
, pp. 1258-1268
-
-
Wu, B.1
Joshi, A.2
Ren, S.3
Ng, C.4
-
20
-
-
32244436150
-
Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers
-
C.M. Ng, E. Stefanich, B.S. Anand, P.J. Fielder, and L. Vaickus Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers Pharm Res 23 2006 95 103
-
(2006)
Pharm Res
, vol.23
, pp. 95-103
-
-
Ng, C.M.1
Stefanich, E.2
Anand, B.S.3
Fielder, P.J.4
Vaickus, L.5
-
21
-
-
84877885008
-
Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: Applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design
-
Y. Vugmeyster, C. Rohde, M. Perreault, R.E. Gimeno, and P. Singh Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design MAbs 5 2013 373 383
-
(2013)
MAbs
, vol.5
, pp. 373-383
-
-
Vugmeyster, Y.1
Rohde, C.2
Perreault, M.3
Gimeno, R.E.4
Singh, P.5
-
22
-
-
77949739818
-
The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis
-
A.M. Betts, T.H. Clark, J. Yang, J.L. Treadway, M. Li, M.A. Giovanelli, and et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis J Pharmacol Exp Ther 333 2010 2 13
-
(2010)
J Pharmacol Exp Ther
, vol.333
, pp. 2-13
-
-
Betts, A.M.1
Clark, T.H.2
Yang, J.3
Treadway, J.L.4
Li, M.5
Giovanelli, M.A.6
-
23
-
-
84889828313
-
The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics
-
S.C. Devanaboyina, S.M. Lynch, R.J. Ober, S. Ram, D. Kim, A. Puig-Canto, and et al. The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics MAbs 5 2013 851 859
-
(2013)
MAbs
, vol.5
, pp. 851-859
-
-
Devanaboyina, S.C.1
Lynch, S.M.2
Ober, R.J.3
Ram, S.4
Kim, D.5
Puig-Canto, A.6
-
24
-
-
84859510090
-
Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9
-
J. Chaparro-Riggers, H. Liang, R.M. DeVay, L. Bai, J.E. Sutton, W. Chen, and et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 J Biol Chem 287 2012 11090 11097
-
(2012)
J Biol Chem
, vol.287
, pp. 11090-11097
-
-
Chaparro-Riggers, J.1
Liang, H.2
DeVay, R.M.3
Bai, L.4
Sutton, J.E.5
Chen, W.6
-
25
-
-
84905222360
-
Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution
-
M.W. Traxlmayr, E. Lobner, C. Hasenhindl, G. Stadlmayr, C. Oostenbrink, F. Ruker, and et al. Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution Biotechnol J 9 2014 1013 1022
-
(2014)
Biotechnol J
, vol.9
, pp. 1013-1022
-
-
Traxlmayr, M.W.1
Lobner, E.2
Hasenhindl, C.3
Stadlmayr, G.4
Oostenbrink, C.5
Ruker, F.6
-
26
-
-
84862638874
-
Clinical chemistry of human FcRn transgenic mice
-
C. Stein, L. Kling, G. Proetzel, D.C. Roopenian, M.H. de Angelis, E. Wolf, and et al. Clinical chemistry of human FcRn transgenic mice Mamm Genome 23 2012 259 269
-
(2012)
Mamm Genome
, vol.23
, pp. 259-269
-
-
Stein, C.1
Kling, L.2
Proetzel, G.3
Roopenian, D.C.4
De Angelis, M.H.5
Wolf, E.6
-
27
-
-
8244226656
-
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
-
L.P. Boulet, K.R. Chapman, J. Cote, S. Kalra, R. Bhagat, V.A. Swystun, and et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response Am J Respir Crit Care Med 155 1997 1835 1840
-
(1997)
Am J Respir Crit Care Med
, vol.155
, pp. 1835-1840
-
-
Boulet, L.P.1
Chapman, K.R.2
Cote, J.3
Kalra, S.4
Bhagat, R.5
Swystun, V.A.6
-
28
-
-
0242585330
-
Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes
-
M.A. Alyanakian, E. Bernatowska, J.M. Scherrmann, P. Aucouturier, and J.L. Poplavsky Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes Vox Sang 84 2003 188 192
-
(2003)
Vox Sang
, vol.84
, pp. 188-192
-
-
Alyanakian, M.A.1
Bernatowska, E.2
Scherrmann, J.M.3
Aucouturier, P.4
Poplavsky, J.L.5
-
29
-
-
34248187996
-
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
-
A.W. Tolcher, M. Mita, N.J. Meropol, M. von Mehren, A. Patnaik, K. Padavic, and et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 J Clin Oncol 25 2007 1390 1395
-
(2007)
J Clin Oncol
, vol.25
, pp. 1390-1395
-
-
Tolcher, A.W.1
Mita, M.2
Meropol, N.J.3
Von Mehren, M.4
Patnaik, A.5
Padavic, K.6
-
30
-
-
59449094255
-
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: A phase I, pharmacokinetic, and biological correlative study
-
A.D. Ricart, A.W. Tolcher, G. Liu, K. Holen, G. Schwartz, M. Albertini, and et al. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study Clin Cancer Res 14 2008 7924 7929
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7924-7929
-
-
Ricart, A.D.1
Tolcher, A.W.2
Liu, G.3
Holen, K.4
Schwartz, G.5
Albertini, M.6
-
31
-
-
84910019975
-
Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody
-
K. Haraya, T. Tachibana, M. Nanami, and M. Ishigai Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody Xenobiotica 44 2014 1127 1134
-
(2014)
Xenobiotica
, vol.44
, pp. 1127-1134
-
-
Haraya, K.1
Tachibana, T.2
Nanami, M.3
Ishigai, M.4
-
32
-
-
84877898507
-
Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities
-
S.H. Tam, S.G. McCarthy, K. Brosnan, K.M. Goldberg, and B.J. Scallon Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities MAbs 5 2013 397 405
-
(2013)
MAbs
, vol.5
, pp. 397-405
-
-
Tam, S.H.1
McCarthy, S.G.2
Brosnan, K.3
Goldberg, K.M.4
Scallon, B.J.5
-
33
-
-
0027320006
-
Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies
-
A.T. Jones, and H.J. Ziltener Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies Blood 82 1993 1133 1141
-
(1993)
Blood
, vol.82
, pp. 1133-1141
-
-
Jones, A.T.1
Ziltener, H.J.2
-
34
-
-
0024474425
-
Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease
-
T. Moritz, N. Niederle, J. Baumann, D. May, E. Kurschel, R. Osieka, and et al. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease Cancer Immunol Immunother 29 1989 144 150
-
(1989)
Cancer Immunol Immunother
, vol.29
, pp. 144-150
-
-
Moritz, T.1
Niederle, N.2
Baumann, J.3
May, D.4
Kurschel, E.5
Osieka, R.6
-
35
-
-
84879555640
-
Elevated concentration of oxidized LDL together with poor cardiorespiratory and abdominal muscle fitness predicts metabolic syndrome in young men
-
J. Kosola, J.P. Vaara, M. Ahotupa, H. Kyrolainen, M. Santtila, N. Oksala, and et al. Elevated concentration of oxidized LDL together with poor cardiorespiratory and abdominal muscle fitness predicts metabolic syndrome in young men Metabolism 62 2013 992 999
-
(2013)
Metabolism
, vol.62
, pp. 992-999
-
-
Kosola, J.1
Vaara, J.P.2
Ahotupa, M.3
Kyrolainen, H.4
Santtila, M.5
Oksala, N.6
-
36
-
-
0017193927
-
The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma
-
T.A. Waldmann, A. Iio, M. Ogawa, O.R. McIntyre, and W. Strober The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma J Immunol 117 1976 1139 1144
-
(1976)
J Immunol
, vol.117
, pp. 1139-1144
-
-
Waldmann, T.A.1
Iio, A.2
Ogawa, M.3
McIntyre, O.R.4
Strober, W.5
-
38
-
-
84893653708
-
Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys
-
W. Wang, X. Wang, R. Doddareddy, D. Fink, T. McIntosh, H.M. Davis, and et al. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys AAPS J 16 2014 129 139
-
(2014)
AAPS J
, vol.16
, pp. 129-139
-
-
Wang, W.1
Wang, X.2
Doddareddy, R.3
Fink, D.4
McIntosh, T.5
Davis, H.M.6
-
39
-
-
77649211091
-
Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects
-
Z. Xu, Q. Wang, Y. Zhuang, B. Frederick, H. Yan, E. Bouman-Thio, and et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects J Clin Pharmacol 50 2010 276 284
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 276-284
-
-
Xu, Z.1
Wang, Q.2
Zhuang, Y.3
Frederick, B.4
Yan, H.5
Bouman-Thio, E.6
-
40
-
-
84877036468
-
Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies
-
Y. Zhu, Q. Wang, B. Frederick, E. Bouman-Thio, J.C. Marini, M. Keen, and et al. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies Clin Drug Investig 33 2013 291 301
-
(2013)
Clin Drug Investig
, vol.33
, pp. 291-301
-
-
Zhu, Y.1
Wang, Q.2
Frederick, B.3
Bouman-Thio, E.4
Marini, J.C.5
Keen, M.6
-
41
-
-
0031663081
-
Antibody affinity maturation using bacterial surface display
-
P.S. Daugherty, G. Chen, M.J. Olsen, B.L. Iverson, and G. Georgiou Antibody affinity maturation using bacterial surface display Protein Eng 11 1998 825 832
-
(1998)
Protein Eng
, vol.11
, pp. 825-832
-
-
Daugherty, P.S.1
Chen, G.2
Olsen, M.J.3
Iverson, B.L.4
Georgiou, G.5
|